Tower Research Capital LLC TRC Takes Position in Axsome Therapeutics Inc (NASDAQ:AXSM)

Tower Research Capital LLC TRC purchased a new stake in Axsome Therapeutics Inc (NASDAQ:AXSM) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 13,352 shares of the company’s stock, valued at approximately $344,000.

Several other hedge funds have also recently made changes to their positions in AXSM. BlackRock Inc. grew its holdings in shares of Axsome Therapeutics by 263.1% in the 2nd quarter. BlackRock Inc. now owns 1,690,522 shares of the company’s stock valued at $43,531,000 after buying an additional 1,224,935 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Axsome Therapeutics in the 2nd quarter valued at $6,365,000. EAM Global Investors LLC acquired a new position in shares of Axsome Therapeutics in the 1st quarter valued at $1,211,000. Bank of New York Mellon Corp grew its holdings in shares of Axsome Therapeutics by 87.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 164,396 shares of the company’s stock valued at $4,233,000 after buying an additional 76,555 shares during the period. Finally, Moody Aldrich Partners LLC acquired a new position in shares of Axsome Therapeutics in the 2nd quarter valued at $1,843,000. 53.02% of the stock is owned by institutional investors.

NASDAQ:AXSM traded up $0.32 on Friday, hitting $27.69. 8,663 shares of the company’s stock were exchanged, compared to its average volume of 493,309. The firm has a 50-day moving average price of $25.49 and a 200-day moving average price of $21.11. The company has a debt-to-equity ratio of 0.72, a current ratio of 4.18 and a quick ratio of 4.18. Axsome Therapeutics Inc has a 52 week low of $1.94 and a 52 week high of $30.50. The company has a market cap of $943.80 million, a P/E ratio of -24.13 and a beta of 2.64.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). On average, research analysts expect that Axsome Therapeutics Inc will post -1.49 earnings per share for the current fiscal year.

AXSM has been the subject of a number of research analyst reports. ValuEngine raised shares of Axsome Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 4th. William Blair initiated coverage on shares of Axsome Therapeutics in a research note on Wednesday. They issued an “outperform” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $35.00 target price (up from $25.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 28th. SunTrust Banks initiated coverage on shares of Axsome Therapeutics in a research note on Tuesday, May 28th. They issued a “buy” rating for the company. Finally, BidaskClub raised shares of Axsome Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $30.83.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

See Also: What are the benefits of buying treasury bonds?

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit